Role of Endogenous GLP-1 and its Agonists in Osteopenia and Osteoporosis: But We Little Know Until Tried

Author(s): Athanasia Papazafiropoulou, Nikolaos Papanas, Stavros Pappas, Efstratios Maltezos

Journal Name: Current Diabetes Reviews

Volume 10 , Issue 1 , 2014

Become EABM
Become Reviewer
Call for Editor


The present brief review looks at the evidence on the role of GLP-1 and its agonists in osteopenia and osteoporosis in type 2 diabetes (T2DM). There is accumulating data to suggest a favourable effect of GLP-1 on bone metabolism. However, most data is from experimental studies, while clinical confirmation is still inadequate. Moreover, little is known on the precise mechanisms underlying these effects. Therefore, we need randomised clinical trials in T2DM patients to learn more on the action of GLP-1 on bone metabolism and its potential clinical implications.

Keywords: Bone metabolism, fractures, GLP-1, incretins, type 2 diabetes mellitus.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [43 - 47]
Pages: 5
DOI: 10.2174/1573399810666140217114848
Price: $65

Article Metrics

PDF: 49